CN117618340A - 一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 - Google Patents
一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 Download PDFInfo
- Publication number
- CN117618340A CN117618340A CN202311372204.3A CN202311372204A CN117618340A CN 117618340 A CN117618340 A CN 117618340A CN 202311372204 A CN202311372204 A CN 202311372204A CN 117618340 A CN117618340 A CN 117618340A
- Authority
- CN
- China
- Prior art keywords
- oil solution
- dragon
- wound
- dragon oil
- diabetic foot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 208000027418 Wounds and injury Diseases 0.000 title claims description 77
- 206010052428 Wound Diseases 0.000 title claims description 76
- 208000008960 Diabetic foot Diseases 0.000 title claims description 21
- 230000001684 chronic effect Effects 0.000 title description 2
- 239000003921 oil Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 8
- 239000003906 humectant Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 235000012907 honey Nutrition 0.000 claims abstract description 4
- 235000019198 oils Nutrition 0.000 claims description 47
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 210000002683 foot Anatomy 0.000 claims description 13
- 210000003414 extremity Anatomy 0.000 claims description 11
- 210000003371 toe Anatomy 0.000 claims description 11
- 239000002390 adhesive tape Substances 0.000 claims description 9
- 229940099259 vaseline Drugs 0.000 claims description 9
- 239000010408 film Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 7
- 210000000689 upper leg Anatomy 0.000 claims description 6
- 239000008399 tap water Substances 0.000 claims description 4
- 235000020679 tap water Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 241001116389 Aloe Species 0.000 claims description 3
- 241001474374 Blennius Species 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 3
- 241000238371 Sepiidae Species 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 229930013930 alkaloid Natural products 0.000 claims description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 3
- 235000011399 aloe vera Nutrition 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- 239000003945 anionic surfactant Substances 0.000 claims description 3
- 239000002639 bone cement Substances 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 3
- 239000003093 cationic surfactant Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- GQEZCXVZFLOKMC-UHFFFAOYSA-N n-alpha-hexadecene Natural products CCCCCCCCCCCCCCC=C GQEZCXVZFLOKMC-UHFFFAOYSA-N 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 150000003505 terpenes Chemical class 0.000 claims description 3
- 229940074410 trehalose Drugs 0.000 claims description 3
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 3
- 239000012498 ultrapure water Substances 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000035876 healing Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 230000008439 repair process Effects 0.000 abstract description 10
- 239000007788 liquid Substances 0.000 abstract description 9
- 230000004089 microcirculation Effects 0.000 abstract description 9
- 210000000170 cell membrane Anatomy 0.000 abstract description 8
- 150000002632 lipids Chemical class 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 7
- 230000035764 nutrition Effects 0.000 abstract description 6
- 230000002503 metabolic effect Effects 0.000 abstract description 4
- 230000002950 deficient Effects 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 24
- 238000001804 debridement Methods 0.000 description 14
- 208000025865 Ulcer Diseases 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000036770 blood supply Effects 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000001223 reverse osmosis Methods 0.000 description 7
- 206010017711 Gangrene Diseases 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010039509 Scab Diseases 0.000 description 5
- 230000004992 fission Effects 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 4
- 210000003041 ligament Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 description 4
- 206010011985 Decubitus ulcer Diseases 0.000 description 3
- 206010049927 Dry gangrene Diseases 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000002266 amputation Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 206010007882 Cellulitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 244000124209 Crocus sativus Species 0.000 description 2
- 235000015655 Crocus sativus Nutrition 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 235000019498 Walnut oil Nutrition 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000013974 saffron Nutrition 0.000 description 2
- 239000004248 saffron Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000008170 walnut oil Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明适用于医疗技术领域,提供了一种龙油溶液,所述龙油溶液包括组分:油脂类混合物、乳化剂、水、蜂蜜、保湿剂、维生素、抗氧化剂和成膜剂;本发明通过液体敷料对创面起到遮蔽效应的方法,清除损伤组织的代谢产物,模仿微循环系统,形成外微循环组织系统;通过密闭环境下的介导营养作用,促进缺损细胞膜或组织的脂修复,加快受损组织创面的愈合。
Description
技术领域
本发明属于医疗技术领域,尤其涉及一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法。
背景技术
根据IDF2019年公布的最新数据,中国糖尿病患者人数为1.16亿。其中糖尿病足患病率已达4%,患者总人数超过450万。目前,我国三级医院中27.3%的截肢发生在糖尿病患者中;而这些糖尿病患者中,往往都是因足部出现糖尿病足而导致的截肢,这些糖尿病患者截肢后,6个月内死亡率为20%,常规治疗5年的生存率仅44%,因此糖尿病足已成为严重危害人民生命健康的疾病。
公开号为CN110585234的中国发明专利,公开了一种采用氯化钠溶液对压疮进行清创的方法。该方法包括以下步骤:用质量浓度为0.5~2%的生理盐水清洗压疮伤口,然后将经质量浓度为0.5~15%的氯化钠浸泡后的纱布覆盖于伤口上即可。上述专利采用10%氯化钠对III期压疮感染伤口进行清创,利用其在创面局部释放高浓度的氯离子,破坏细菌细胞内环境使其失活达到清创的作用,同时其建立的高渗环境,有效促进组织间水肿的吸收,维持局部稳定的湿性环境,达到促进创面恢复的作用。
但是上述专利有以下不足之处:
上述专利通过氯化钠对III期压疮感染伤口进行清创,利用其在创面局部释放高浓度的氯离子,破坏细菌细胞内环境使其失活达到清创的作用,这种方式虽然能够达到清创效果,但是不能促进缺损细胞膜或组织的脂修复,不能加快受损组织创面的愈合。
发明内容
本发明提供一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法,旨在解决目前的清创方式不能加快受损组织创面愈合的问题。
为了实现上述目的,本发明采用如下技术方案:
一种龙油溶液,所述龙油溶液包括组分:油脂类混合物、乳化剂、水、蜂蜜、保湿剂、维生素、抗氧化剂和成膜剂;此方案中通过设置龙油溶液,该龙油溶液通过脂溶性脂质成分与活性物质相容,可为正常细胞和受损细胞提供保护和营养。
优选的,按照重量配比:
优选的,所述油脂类混合物由墨鱼骨、藏红花、核桃油和菜籽油制成;此方案中通过设置油脂类混合物,该油脂类混合物可为龙油溶液提供多种脂溶性营养物质,使龙油溶液富含不饱和脂肪酸、油酸、亚油酸、亚麻酸等有效活性脂类物质。
优选的,所述乳化剂为阴离子型表面活性剂、阳离子型表面活性剂、非离子型表面活性剂中的一种;此方案中通过设置乳化剂,该乳化剂能够改善乳浊液中各种构成相之间的表面张力,使之形成均匀稳定的分散体系或乳浊液的物质。
优选的,所述水为去离子水、超纯水和自来水中的一种;此方案中通过设置水,该水最好为离子水,离子水相对于自来水来说其杂质更少;并且该离子水具有杀菌、消毒、敛肤、美容的作用。弱酸性离子水的水分子团小,渗透力强,溶氧性高,能消除自由基,所以具有美容收敛毛孔的作用。弱酸性离子水外用对皮肤病、烫伤、清洁皮肤和愈合伤口都有较好的效果。
优选的,所述保湿剂为芦荟、甲壳素、尿素、海藻提取物中的两种或两种以上的混合物;此方案中通过设置保湿剂,该保湿剂能够发挥改良细胞外环境的作用,使细胞再生及增殖分化成为可能。这种湿性环境,调节创面细胞内和细胞外的微环境,促进毛细血管再生;并且湿润环境可以减少或避免结痂形成,避免新生肉芽组织的再次机械性损伤,保护创面。血管内皮细胞生成活跃,为组织提供营养成分,耐性代谢加强,快速排除耐性代谢产物,减少疼痛,增加患者舒适感。
优选的,所述抗氧化剂为黄酮、生物碱和萜类中的一种;此方案中通过设置抗氧化剂,该抗氧化剂具有抗炎、抗氧化等活性,能够用于治疗感染、炎症、损伤等疾病。
优选的,所述成膜剂为壳聚糖、明胶、琼脂、骨胶、羧甲基纤维素、卡波姆、海藻酸钠、海藻糖、VP/十六碳烯共聚物、聚乙烯基吡咯烷酮、聚乙烯醇、聚乙二醇中的一种;此方案中通过设置成膜剂,该成膜剂可以为受损细胞和组织提供一个保护膜,有效抑制微生物和细菌病毒等繁殖和分裂,最大程度的使创面保持无感染状态。
一种采用龙油溶液对糖尿病足及慢创进行清创的方法,其特征在于,
包括以下步骤:
S1,用生理盐水清洗糖尿病足伤口。
S2,将糖尿病足伤口擦干后,取龙油溶液均匀涂抹在患肢处。
此方案中该步骤1和步骤2相结合可达到清创疏通的目的。
S3,用无菌敷贴贴敷于糖尿病足伤口处。
S4,用凡士林纱布盖在无菌敷贴上。
此方案中该步骤4的目的是为了防止油液反渗透。
S5,用医用纱布和胶带对伤口处进行包扎。
S6,将手指放在从脚到大腿15-20公分的位置处,从脚趾往心脏方向进行揉搓直至发热;此方案中该步骤6的目的是为了帮助血管疏通、恢复血供,促使血红细胞的加速裂变和增殖移行,打通血液微循环促生肌。
与现有技术相比,本发明的有益效果是:本发明通过液体敷料对创面起到遮蔽效应的方法,清除损伤组织的代谢产物,模仿微循环系统,形成外微循环组织系统;通过密闭环境下的介导营养作用,促进缺损细胞膜或组织的脂修复,加快受损组织创面的愈合。
附图说明
为了更清楚地说明本发明具体实施方式或现有技术中的技术方案,下面将对具体实施方式或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明的流程图。
具体实施方式
下面将结合附图对本发明的技术方案进行清楚、完整地描述,显然,所描述的实施例是本发明一部分实施例,而不是全部的实施例。
通常在此处附图中描述和显示出的本发明实施例的组件可以以各种不同的配置来布置和设计。因此,以下对在附图中提供的本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。
基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在本发明的描述中,需要说明的是,术语“中心”、“上”、“下”、“左”、“右”、“竖直”、“水平”、“内”、“外”等指示的方位或位置关系为基于附图所示的方位或位置关系,仅是为了便于描述本发明和简化描述,而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作,因此不能理解为对本发明的限制。此外,术语“第一”、“第二”、“第三”仅用于描述目的,而不能理解为指示或暗示相对重要性。
在本发明的描述中,需要说明的是,除非另有明确的规定和限定,术语“安装”、“相连”、“连接”应做广义理解,例如,可以是固定连接,也可以是可拆卸连接,或一体地连接;可以是机械连接,也可以是电连接;可以是直接相连,也可以通过中间媒介间接相连,可以是两个元件内部的连通。对于本领域的普通技术人员而言,可以具体情况理解上述术语在本发明中的具体含义。
一种龙油溶液,龙油溶液包括组分:油脂类混合物、乳化剂、水、蜂蜜、保湿剂、维生素、抗氧化剂和成膜剂。
进一步的,油脂类混合物:1%-15%
进一步的,油脂类混合物由墨鱼骨、藏红花、核桃油和菜籽油制成。
进一步的,乳化剂为阴离子型表面活性剂、阳离子型表面活性剂、非离子型表面活性剂中的一种。
进一步的,水为去离子水、超纯水和自来水中的一种。
进一步的,保湿剂为芦荟、甲壳素、尿素、海藻提取物中的两种或两种以上的混合物。
进一步的,抗氧化剂为黄酮、生物碱和萜类中的一种。
进一步的,成膜剂为壳聚糖、明胶、琼脂、骨胶、羧甲基纤维素、卡波姆、海藻酸钠、海藻糖、VP/十六碳烯共聚物、聚乙烯基吡咯烷酮、聚乙烯醇、聚乙二醇中的一种。
具体的,该龙油溶液可对细胞膜脂进行修复,修复的方式是通过影响细胞膜的脂质双嵌结构,促使细胞再生的可能,在细胞受损时提供脂溶性营养物质(简称龙油溶液),修复受损组织,直接影响脂质双嵌结构,为组织细胞生长提供良好生长环境,促使损伤细胞对初期的记忆恢复具有良好的生理效应,通过影响组织代谢,从而让损伤细胞成为再生细胞的可能。
该龙油溶液可为正常细胞和受损细胞提供保护和营养:
①保护细胞:为保护损伤细胞,给受损细胞提供修复的稳定生长环境,并有保暖、防止细胞内物质外溢的作用。
②营养细胞:为受损细胞和正常细胞提供氨基酸(胨、肽)、电解质、脂肪、水分子、维生素等多种活性营养物质,这些营养物质通过细胞膜通道对脂肪双嵌结构膜内外形成压力差的作用,以及细胞膜的感知效应,直接进入细胞内部,为细胞内亚分子结构提供营养物质,使得组织恢复正常信息传递和得以转运实现。
该龙油溶液有利于坏死组织与纤维蛋白的溶解,可为创面提供稳定的湿性愈合环境。在湿性愈合时,创面渗出物中含有组织蛋白溶解酶,可促进这些组织的溶解与吸收,去除坏死组织,促进肉芽组织进行生长。
请参阅图1,一种采用龙油溶液对糖尿病足及慢创进行清创的方法,包括以下步骤:
S1,用生理盐水清洗糖尿病足伤口;
S2,将糖尿病足伤口擦干后,取龙油溶液均匀涂抹在患肢处;
S3,用无菌敷贴贴敷于糖尿病足伤口处;
S4,用凡士林纱布盖在无菌敷贴上;
S5,用医用纱布和胶带对伤口处进行包扎;
S6,将手指放在从脚到大腿15-20公分的位置处,从脚趾往心脏方向进行揉搓直至发热。
具体的,本发明通过外部的动力装置及上述的敷料,形成了微动力,对脂肪双嵌结构的细胞膜内外形成压力差的作用,在微环境下加快营养和代谢产物的运动,清除坏死组织和分泌代谢产物,使组织修复的速度加快,受损细胞组织微循环重新建立。
这种治疗方式具有以下特点:
①治愈率高:无需手术,全程低痛疗法,为细胞提供充分的脂溶性活性营养物质,加快受损细胞的恢复,促进损伤的组织细胞再生。同时组织内通过“微压引流”,帮助组织内部渗出液排出,为细胞和受损组织提供良好的生长环境。通过制定科学的治疗方法,帮助患者愈合康复,减轻患者痛苦,治愈率96%以上。
②安全性好:为受损组织和细胞提供物质和营养,提高人体自愈力,治疗手段过程安全无毒副作用。
③疗期短:能够解决糖尿病足医疗难题,同时针对难愈合创面治疗愈合周期缩短50%。
④费用低:新型传统疗法,加快细胞组织愈合,即可减少换药次数的优势。在降低患者经济负担的同时,治疗过程用药量减少,避免药物毒副作用,增强患者自身的免疫力,同比手术疗法费用降低50%-70%。
⑤医护压力小:治疗过程中大量减少繁琐操作流程,减轻医护压力和负担。
综上所述,
(一)、医护人员首先对糖尿病足部状态进行了解,糖尿病足部状态:
1、0级早期病变局部缺血:皮肤无开放性病灶。表现为肢端供血不足,颜色紫绀或苍白,肢端发凉、麻木、感觉迟钝或丧失。肢端刺痛或灼痛,常伴有足趾或足的畸形等。
2、1级浅表开放性溃疡:肢端皮肤有开放性病灶。水疱、血疱、鸡眼或胼胝,冻伤或烫伤及其他皮肤损伤所引起的浅表溃疡,但病灶尚未波及深部组织。
3、2级溃烂至肌肉组织:感染病灶已侵犯深部肌肉组织。常有轻度蜂窝组织炎,多发性脓灶及窦道形成,或感染沿肌间隙扩大,造成足底、足背贯通性溃疡或坏疽,脓性分泌物较多,足或指趾皮肤灶性干性坏疽,但肌腱韧带尚无破坏。
4、3级溃烂至韧带组织:肌腱韧带组织破坏。蜂窝组织炎融合形成大脓腔,脓性分泌物及坏死组织增多,足或少数足趾干性坏疽,但骨质破坏尚不明显。
5、4级溃烂感染至骨质:严重感染已造成骨质破坏,骨髓炎,骨关节破坏或已形成假关节,部分足趾或部分手足发生湿性或干性严重坏疽或坏死。
6、5级大面积溃烂感染坏疽:足的大部或全部感染或缺血,导致严重的湿性或干性坏疽,肢端变黑,常波及踝关节及小腿。
(二)糖足等级诊疗方法:
1、微动态辩证阶段:
①患者沟通(当天):患者做系列检查(血糖、动脉造影、骨髓炎必要排查),了解患者一般基本信息及相关并发症,以及过往治疗史、过敏史等。
②病因分析(同天):准确且详尽告知患者可能存在的病症发展情况以及康复疗程周期,让患者透明化治疗,告知溃疡患者使用技术治疗后可能会出现黑变和坏疽的情况,属于患者肌体组织内部已经病变和坏死呈现的正常现象。
③疗愈方案(同天):根据诊断结果和病因,给患者提供对应辨证判断轻症、中症、重症的疗愈方案。
2、微动态论治阶段:
0级:早期病变局部缺血
修复周期:15天
Step1涂油:先将患肢清洗擦干后,取适量龙油溶液均匀涂抹在患肢处。
step 2修复:需要从足趾、足底、内外踝、小腿及膝关节以上15cm处来回搓至手掌微微发热吸收(约20分钟左右),帮助出管疏通、恢复血供血红细胞的加速裂变和增殖移行。
使用次数:一天2次早晚各一次,14天为一周期。
注意事项:在涂、搓过程中忌揉压按挤,主要是往心脏方向均匀搓(上势用力下势轻柔)。
1级-2级:浅表开放性溃疡
愈合周期:20天
step 1清创疏通(3天):使用[龙油溶液液体伤口敷料]产品对伤口进行清创(避免用双氧水和碘伏清理),用(无菌敷贴),根据伤口大小剪裁后“抖乱”直接填塞贴敷于创面和患处,再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎;
同时让患者家属帮助在患者从脚到大腿位置15公分-20公分位置,从脚趾往心脏方向进行揉搓至微微发热,帮助血接受修改管疏通、恢复血供,促使血红细胞的加速裂变和增殖移行,打通血液微循环促生肌。
step 2生肌(10天):清理伤口保持干燥清洁,在创面内部滴入组织再生液,保持创面湿润,同时使用脂修复产品(无菌敷贴),根据伤口大小剪裁后“抖乱”直接填塞贴敷于创面和患处,再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎固定;修复血红细胞和血管内皮细胞、阻止新鲜血液渗出。
step 2愈合(7天):表皮还原,恢复部分干细胞记忆及功能、使老化坏死皮质褪掉,新生皮肤生成,促进完全愈合。
更换次数:前三天每天更换2次,三天后每天更换1次,14天为一个周期。
3级:腔洞肌肉韧带溃疡
愈合周期:30天
step 1疏通(5天):使用[龙油溶液液体伤口敷料]产品对伤口进行清创(避免用双氧水和碘伏清理),用无菌敷贴,根据伤口大小任意剪裁后“抖乱”直接填塞贴敷于创面和患处,再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎;
同时让患者家属帮助在患者从脚到大腿位置15公分-20公分位置,从脚趾往心脏方向进行揉搓至微微发热,帮助出管疏通、恢复血供,促使血红细胞的加速裂变和增殖移行,打通血液微循环促生肌。
step 2清创去腐(5天):创面有黑痂或坏死组织可先用剪刀去除痂皮或在结痂上用刀片划线,可加快吸收,加快溶痂速度。使用脂修复敷料全覆盖创面,加快自溶性清创,外盖纱布则需每天更换1-2次。若创面无法清创的,可直接用无菌敷贴油纱包裹(重复4小时换1次)等待组织液化后再清除坏死组织。
step 3生肌(10天):清理伤口保持干燥清洁,针对腔洞的创面在创面内部滴入组织再生液,保持创面湿润,同时使用脂修复产品(无菌敷贴),根据伤口大小任意剪裁后“抖乱”直接填塞贴敷于创面和患处,一定要填满、塞实、接触到伤口基底,针对小而深的腔洞可预先将龙油溶液-液体伤口敷料注入5ml的注射器,然后再打入腔洞再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎固定;修复血红细胞和血管内皮细胞、阻止新鲜血液渗出。
step 4愈合(10天):表皮还原,恢复部分干细胞记忆及功能、使老化坏死皮质褪掉,新生皮肤生成,促进完全愈合。
护理次数:前三天每天更换2次,三天后每天更换1次,14天为一个周期。
溃疡重症(4-5级感染坏疽型溃疡)
愈合周期:45天
step 1清创疏通(5天):使用[龙油溶液液体伤口敷料]产品对伤口进行清创(避免用双氧水和碘伏清理),出现的湿性或干性坏疽这种完全坏死组织,需用剪刀或手术进行清理清除后,使用脂修复敷料(无菌敷贴)根据伤口大小剪裁“抖乱”填塞贴敷于患处,全覆盖创面,再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎,前3-4天观察创面周围血供恢复情况,疼痛/血供等创面的变化,初步使用每8小时换药一次,等待溃烂面周围出现黑红分明的清创分界线,加快自溶性清创,外盖纱布则需每天更换1-2次。
同时让患者家属帮助在患者从脚到大腿位置15公分-20公分位置,从脚趾往心脏方向进行揉搓至微微发热,帮助出管疏通、恢复血供血红细胞的加速裂变和增殖移行,打通血液微循环促生肌。
step 3去腐(5天):使用脂修复敷料全覆盖创面,外盖纱布则需每天更换1-2次。加快自溶性组织的去腐,减少分泌物渗出。
step 4生肌(20天):针对腔洞的创面在创面内部滴入组织再液,保持创面湿润,同时使用脂修复产品(无菌敷贴),根据伤口大小剪裁后“抖乱”直接填塞贴敷于创面和患处,一定要填满、塞实、接触到伤口基底,针对小而深的腔洞可预先将龙油溶液-液体伤口敷料注入5ml的注射器,然后再打入腔洞再使用凡士林纱布盖上防止油液反渗透,最后用医用纱布、胶带进行包扎固定;修复血红细胞和血管内皮细胞、防止新鲜血液渗出。
step 5愈合(15天):表皮还原,恢复部分干细胞记忆及功能、使老化坏死皮质褪掉,新生皮肤生成,促进完全愈合。
护理次数:前三天每天更换2次,三天后每天更换1次,14天为一个周期。
3、康复阶段:
①表皮恢复:恢复部分干细胞记忆及功能,皮肤表面沉积色着淡化康复阶段。
②康复养护(每周1次):患者对肢体进行每周1-3次的预防保养护理,帮助促进血液循环,避免再次出现其他病变。
上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其他实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (9)
1.一种龙油溶液,其特征在于,所述龙油溶液包括组分:油脂类混合物、乳化剂、水、蜂蜜、保湿剂、维生素、抗氧化剂和成膜剂。
2.如权利要求1所述的龙油溶液,其特征在于,按照重量配比:
3.如权利要求1所述的龙油溶液,其特征在于:
所述油脂类混合物由墨鱼骨、藏红花、核桃油和菜籽油制成。
4.如权利要求1所述的龙油溶液,其特征在于:
所述乳化剂为阴离子型表面活性剂、阳离子型表面活性剂、非离子型表面活性剂中的一种。
5.如权利要求1所述的龙油溶液,其特征在于:
所述水为去离子水、超纯水和自来水中的一种。
6.如权利要求1所述的龙油溶液,其特征在于:
所述保湿剂为芦荟、甲壳素、尿素、海藻提取物中的两种或两种以上的混合物。
7.如权利要求1所述的龙油溶液,其特征在于:
所述抗氧化剂为黄酮、生物碱和萜类中的一种。
8.如权利要求1所述的龙油溶液,其特征在于:
所述成膜剂为壳聚糖、明胶、琼脂、骨胶、羧甲基纤维素、卡波姆、海藻酸钠、海藻糖、VP/十六碳烯共聚物、聚乙烯基吡咯烷酮、聚乙烯醇、聚乙二醇中的一种。
9.如权利要求1所述的采用龙油溶液对糖尿病足及慢创进行清创的方法,其特征在于,
包括以下步骤:
S1,用生理盐水清洗糖尿病足伤口;
S2,将糖尿病足伤口擦干后,取龙油溶液均匀涂抹在患肢处;
S3,用无菌敷贴贴敷于糖尿病足伤口处;
S4,用凡士林纱布盖在无菌敷贴上;
S5,用医用纱布和胶带对伤口处进行包扎;
S6,将手指放在从脚到大腿15-20公分的位置处,从脚趾往心脏方向进行揉搓直至发热。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311372204.3A CN117618340A (zh) | 2023-10-20 | 2023-10-20 | 一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311372204.3A CN117618340A (zh) | 2023-10-20 | 2023-10-20 | 一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117618340A true CN117618340A (zh) | 2024-03-01 |
Family
ID=90022464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311372204.3A Pending CN117618340A (zh) | 2023-10-20 | 2023-10-20 | 一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117618340A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113209199A (zh) * | 2021-05-31 | 2021-08-06 | 安徽济梵生医药生物科技有限公司 | 一种促进创面愈合的纯中药油剂及其使用方法 |
CN115813973A (zh) * | 2022-12-29 | 2023-03-21 | 中国人民解放军军事科学院军事医学研究院 | 龙油在制备防治放射性肠炎药中的应用 |
-
2023
- 2023-10-20 CN CN202311372204.3A patent/CN117618340A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113209199A (zh) * | 2021-05-31 | 2021-08-06 | 安徽济梵生医药生物科技有限公司 | 一种促进创面愈合的纯中药油剂及其使用方法 |
CN115813973A (zh) * | 2022-12-29 | 2023-03-21 | 中国人民解放军军事科学院军事医学研究院 | 龙油在制备防治放射性肠炎药中的应用 |
Non-Patent Citations (1)
Title |
---|
FILIS CURTI, ET AL.: "Development of Biocomposite Alginate-Cuttlebone-Gelatin 3D Printing Inks Designed for Scaffolds with Bone Regeneration Ptential", MARINE DRUGS, vol. 20, no. 11, 26 October 2022 (2022-10-26), pages 670 - 692 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2523889C2 (ru) | Применение фармацевтических композиций в изготовлении лекарственных средств для лечения диабетических язв | |
JP2019517533A (ja) | 皮膚の種々の損傷創面の治療の外用医薬組成物およびその調製方法 | |
CN106728727A (zh) | 一种治疗疮疡的药膏及其制备方法 | |
US20140044667A1 (en) | Healing composition for topical application | |
Khorasani et al. | The effects of Aloe Vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebo-controlled study | |
CN113209199A (zh) | 一种促进创面愈合的纯中药油剂及其使用方法 | |
CA2627223C (en) | Wound-healing pharmaceutical compositions in the form of a sterile powder based on amino acids and sodium hyaluronate | |
WO2020144564A1 (en) | Composition for the treatment of skin lesions and irritations | |
Niezgoda et al. | Wound treatment options | |
CN117618340A (zh) | 一种龙油溶液及采用龙油溶液对糖尿病足及慢创进行清创的方法 | |
CN101254277B (zh) | 一种治疗烧烫伤的外敷膏剂 | |
Kirsner et al. | Effects of a surfactant-based gel on acute and chronic paediatric wounds: a panel discussion and case series | |
RU2416425C1 (ru) | Масло противопролежневое | |
Liden et al. | Hypochlorous acid: Its multiple uses for wound care | |
CN111544523A (zh) | 一种治疗皮肤溃烂的中药组合物及其应用 | |
CN112206272A (zh) | 一种用于闭合性软组织的外用冷敷凝胶 | |
Weinstein | Update on wound healing: a review of the literature | |
CN112316108A (zh) | 促进及治疗慢性伤口愈合的组合物和方法 | |
CN110801464A (zh) | 三花聚能创伤救急药油及其制备方法 | |
Hon | Safe debridement in the community setting | |
GB2088714A (en) | Pharmaceutical compositions containing allyl isothiocyanate | |
CN113332042B (zh) | 一种导电网络-硅酮复合智能疤痕贴及其制备方法 | |
Józsa et al. | Management of Pediatric Partial-Thickness Burns with Lavanid Gel (Polyhexamethylen Biguanide, Polyhexanide)“Case Reports” | |
CN114010669A (zh) | 一种祛腐生肌软膏及其制备方法和应用 | |
CN101053614B (zh) | 骨肉康外用抗感染粉剂及其配药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |